Hyphens Pharma Extends Metoject® Autoinjector Pen Rights to Thailand and Cambodia

SGX Filings

Oct 16, 2025

Hyphens Pharma International Limited announced on Oct, 16 2025 that its wholly owned unit, Hyphens Pharma Pte. Ltd., has expanded its partnership with Medac Gesellschaft für klinische Spezialpräparate m.b.H. to cover Thailand and Cambodia for the commercialisation of the Metoject® subcutaneous autoinjector pen.

The latest arrangement enlarges a deal signed in Mar, 2025, which had given Hyphens exclusive rights to register and market the product in Singapore, Malaysia, the Philippines and Vietnam.

Metoject® is already authorised in more than 15 countries across Europe, the United States and Japan, and is recognised as a first-line treatment for rheumatoid arthritis under European and American guidelines. The methotrexate‐based injection is also indicated for plaque psoriasis, offering higher bioavailability and fewer gastrointestinal side effects compared with oral methotrexate.

Hyphens stated that the agreement’s extension is not expected to materially affect the group’s net tangible assets or earnings per share for the current financial year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1110762854"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1110762854\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1110762854?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-16 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110762854","market":"sg","top_or_hot":-1,"title":"Hyphens Pharma Extends Metoject® Autoinjector Pen Rights to Thailand and Cambodia","media":"SGX Filings","content":"<p>Hyphens Pharma International Limited announced on Oct, 16 2025 that its wholly owned unit, Hyphens Pharma Pte. Ltd., has expanded its partnership with Medac Gesellschaft für klinische Spezialpräparate m.b.H. to cover Thailand and Cambodia for the commercialisation of the Metoject® subcutaneous autoinjector pen.</p>\n<p>The latest arrangement enlarges a deal signed in Mar, 2025, which had given Hyphens exclusive rights to register and market the product in Singapore, Malaysia, the Philippines and Vietnam.</p>\n<p>Metoject® is already authorised in more than 15 countries across Europe, the United States and Japan, and is recognised as a first-line treatment for rheumatoid arthritis under European and American guidelines. The methotrexate‐based injection is also indicated for plaque psoriasis, offering higher bioavailability and fewer gastrointestinal side effects compared with oral methotrexate.</p>\n<p>Hyphens stated that the agreement’s extension is not expected to materially affect the group’s net tangible assets or earnings per share for the current financial year.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hyphens Pharma Extends Metoject® Autoinjector Pen Rights to Thailand and Cambodia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHyphens Pharma Extends Metoject® Autoinjector Pen Rights to Thailand and Cambodia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083912268\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SGX Filings </p>\n<p class=\"h-time\">2025-10-16 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hyphens Pharma International Limited announced on Oct, 16 2025 that its wholly owned unit, Hyphens Pharma Pte. Ltd., has expanded its partnership with Medac Gesellschaft für klinische Spezialpräparate m.b.H. to cover Thailand and Cambodia for the commercialisation of the Metoject® subcutaneous autoinjector pen.</p>\n<p>The latest arrangement enlarges a deal signed in Mar, 2025, which had given Hyphens exclusive rights to register and market the product in Singapore, Malaysia, the Philippines and Vietnam.</p>\n<p>Metoject® is already authorised in more than 15 countries across Europe, the United States and Japan, and is recognised as a first-line treatment for rheumatoid arthritis under European and American guidelines. The methotrexate‐based injection is also indicated for plaque psoriasis, offering higher bioavailability and fewer gastrointestinal side effects compared with oral methotrexate.</p>\n<p>Hyphens stated that the agreement’s extension is not expected to materially affect the group’s net tangible assets or earnings per share for the current financial year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"1J5.SI","symbol_name":"凯帆药剂国际有限公司","start_time":0,"source_url":"","article_id":"1110762854","we_media_id":"1083912268","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110762854","pubTimestamp":1760616355,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SGX Filings","introduction":"Fastest News on SGX Filings ","home_visible":1,"id":"1083912268","head_image":"https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39"},"summary":"Hyphens Pharma International Limited announced on Oct, 16 2025 that its wholly owned unit, Hyphens Pharma Pte. Ltd., has expanded its partnership with Medac Gesellschaft für klinische...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"1J5.SI":"凯帆药剂国际有限公司"},"translate_title":"Hyphens Pharma扩展Metoject®自动注射器笔在泰国和柬埔寨的权利","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"1J5.SI":1},"content_text":"Hyphens Pharma International Limited announced on Oct, 16 2025 that its wholly owned unit, Hyphens Pharma Pte. Ltd., has expanded its partnership with Medac Gesellschaft für klinische Spezialpräparate m.b.H. to cover Thailand and Cambodia for the commercialisation of the Metoject® subcutaneous autoinjector pen.\nThe latest arrangement enlarges a deal signed in Mar, 2025, which had given Hyphens exclusive rights to register and market the product in Singapore, Malaysia, the Philippines and Vietnam.\nMetoject® is already authorised in more than 15 countries across Europe, the United States and Japan, and is recognised as a first-line treatment for rheumatoid arthritis under European and American guidelines. The methotrexate‐based injection is also indicated for plaque psoriasis, offering higher bioavailability and fewer gastrointestinal side effects compared with oral methotrexate.\nHyphens stated that the agreement’s extension is not expected to materially affect the group’s net tangible assets or earnings per share for the current financial year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}